Suppr超能文献

将卡马西平制成控释制剂并以15N标记药物的混悬液同时口服给健康志愿者后,全身药物吸收与胃肠转运之间的关系。

Relationship between systemic drug absorption and gastrointestinal transit after the simultaneous oral administration of carbamazepine as a controlled-release system and as a suspension of 15N-labelled drug to healthy volunteers.

作者信息

Wilding I R, Davis S S, Hardy J G, Robertson C S, John V A, Powell M L, Leal M, Lloyd P, Walker S M

机构信息

Pharmaceutical Profiles Limited, Highfields Science Park, Nottingham.

出版信息

Br J Clin Pharmacol. 1991 Nov;32(5):573-9. doi: 10.1111/j.1365-2125.1991.tb03954.x.

Abstract
  1. Plasma drug concentrations after a single oral administration of a suspension of carbamazepine (CBZ) and a 20/200 CBZ Oros osmotic pump system were measured in eight healthy male volunteers. The oral suspension contained 100 mg CBZ labelled with the stable isotope nitrogen-15, whilst the Oros contained 200 mg unlabelled CBZ. Plasma concentrations of [15N]-CBZ and CBZ were measured simultaneously by gas chromatography-mass spectrometry. 2. The position of the CBZ Oros (labelled with indium-111) in the gastrointestinal tract was followed by gamma scintigraphy. Plasma drug concentrations after the two treatments were used to relate pharmacokinetic with transit data. 3. The Oros was taken after breakfast and gastric emptying occurred between 1.1- greater than h post-dosing (median, 5.3 h). Small intestinal transit times ranged from 1.5- greater than 3.6 h, with a median of 2.2 h. There were wide individual variations in colonic transit, and the total transit time ranged from 10-60 h (median, 22 h). 4. Relative systemic bioavailability of CBZ from the Oros was reduced compared with that from the suspension (mean dose normalised AUC ratio = 0.69 +/- 0.17; mean dose-normalised AUC ratio = 0.85 +/- 0.13, allowing for actual release from the Oros system). 5. The in vivo absorption of drug into the systemic circulation from the Oros was estimated using the Wagner-Nelson method. This showed that absorption of CBZ was rapid when the Oros was present in the stomach and small intestine, the rate being determined by the release of drug from the system.(ABSTRACT TRUNCATED AT 250 WORDS)
摘要
  1. 在8名健康男性志愿者中测量了单次口服卡马西平(CBZ)混悬液和20/200 CBZ渗透泵系统后的血浆药物浓度。口服混悬液含有100 mg用稳定同位素氮-15标记的CBZ,而渗透泵含有200 mg未标记的CBZ。通过气相色谱-质谱联用同时测量[15N]-CBZ和CBZ的血浆浓度。2. 用γ闪烁显像追踪CBZ渗透泵(用铟-111标记)在胃肠道中的位置。将两种治疗后的血浆药物浓度用于关联药代动力学和转运数据。3. 渗透泵在早餐后服用,给药后1.1至超过1小时(中位数为5.3小时)发生胃排空。小肠转运时间为1.5至超过3.6小时,中位数为2.2小时。结肠转运存在很大的个体差异,总转运时间为10至60小时(中位数为22小时)。4. 与混悬液相比,CBZ从渗透泵的相对全身生物利用度降低(平均剂量标准化AUC比值=0.69±0.17;平均剂量标准化AUC比值=0.85±0.13,考虑到渗透泵系统的实际释放)。5. 采用Wagner-Nelson法估算药物从渗透泵进入体循环的体内吸收情况。结果表明,当渗透泵存在于胃和小肠中时,CBZ的吸收很快,其速率由药物从系统中的释放决定。(摘要截断于250字)

相似文献

2
Absolute bioavailability of carbamazepine after oral administration of a 2% syrup.
Epilepsia. 1990 May-Jun;31(3):334-8. doi: 10.1111/j.1528-1157.1990.tb05384.x.

引用本文的文献

1
Applications of stable isotopes in clinical pharmacology.稳定同位素在临床药理学中的应用。
Br J Clin Pharmacol. 2011 Dec;72(6):879-97. doi: 10.1111/j.1365-2125.2011.04071.x.
3
Extended-release formulations for the treatment of epilepsy.用于治疗癫痫的缓释制剂。
CNS Drugs. 2007;21(9):765-74. doi: 10.2165/00023210-200721090-00005.
7
Pharmacokinetic considerations in gastrointestinal motor disorders.胃肠运动障碍中的药代动力学考量
Clin Pharmacokinet. 1995 Jan;28(1):41-66. doi: 10.2165/00003088-199528010-00005.

本文引用的文献

7
Bioavailability of rectally administered carbamazepine mixture.直肠给药的卡马西平混合物的生物利用度。
Br J Clin Pharmacol. 1987 Dec;24(6):839-41. doi: 10.1111/j.1365-2125.1987.tb03258.x.
9
Gastric emptying of large single unit dosage forms.大的单一单位剂型的胃排空
J Pharm Pharmacol. 1988 Mar;40(3):205-7. doi: 10.1111/j.2042-7158.1988.tb05220.x.
10
Drug delivery to the proximal colon.药物向近端结肠的递送。
J Pharm Pharmacol. 1985 Dec;37(12):874-7. doi: 10.1111/j.2042-7158.1985.tb04992.x.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验